Diabetology
“Diabetes: over 382 million people affected. Diabetic foot represents one of the most serious complications. Plasma exchange can improve both macro and microcirculation”.
The International Diabetes Federation has recently estimated that 8.3% of the adult population, approximately 382 million people, are affected by diabetes, and this number is expected to increase to more than 592 million in less than 25 years. Of these, 15% develop a lower limb ulcer during their lifetime, with 25% progressing to amputation.
Diabetic foot syndrome refers to the set of pathological manifestations directly correlated with diabetic disease complications involving the anatomical structures of the foot.
Due to its unique anatomical location on the periphery of the nervous and vascular systems, the foot of the diabetic patient is particularly susceptible to the effects of complications resulting from peripheral neuropathy, vasculopathy, and infectious processes. Reduced blood flow facilitates the development of ulcerative lesions classified, based on severity, from non-infected superficial ulcers to gangrene, which can lead to amputation.
Currently, the treatment of diabetic foot syndrome involves the administration of medications, revascularization treatments, and plasma exchange, aimed at eliminating from the circulation all substances capable of compromising micro and macro-circulation.
Molecules to remove: LDL; Fibrinogen; Inflammatory Mediators
Recommended Therapies: Double filtration plasmapheresis (DFPP), Cascade Filtration, Plasma Exchange